Riegel v. Medtronic, Inc.
The Court ruled that once the FDA has given a medical device its most rigorous form of approval, federal law blocks state-law injury lawsuits claiming the device's approved design, labeling, or manufacturing was unsafe.
The decision shields device makers from many product-liability suits over FDA-approved devices, though it leaves open lawsuits claiming a company violated the FDA's own requirements.
“State tort law that requires a manufacturer’s catheters to be safer, but hence less effective, than the model the FDA has approved disrupts the federal scheme no less than state regulatory law to the same effect.”
Explaining why state jury verdicts can conflict with FDA-approved device designs just like state regulations can.
How it got here: A federal trial court dismissed most of the Riegels' claims as preempted; the Second Circuit affirmed; the Supreme Court agreed to review the preemption question.
The Case in Depth
What happened
Charles Riegel's doctor used a Medtronic balloon catheter during heart surgery even though it was labeled as unsuitable for his condition; the catheter ruptured when inflated beyond its rated pressure, causing severe injuries. Riegel and his wife Donna sued Medtronic in New York state-law tort, claiming the catheter was defectively designed, labeled, and manufactured. The catheter had gone through the FDA's most demanding review process before reaching the market.
The question before the Court
If the FDA has already approved the exact design and labeling of a medical device, can an injured patient still sue the maker under state injury law?
The Court's answer
No — once a medical device has gone through the FDA's most rigorous review, called premarket approval, a patient generally cannot sue the manufacturer in state court over the device's approved design, labeling, or manufacturing. The Court reasoned that premarket approval creates specific federal safety requirements for that exact device, and a state jury verdict demanding a different, presumably safer design would conflict with what the FDA already decided was an acceptable balance of risks and benefits.
This does not mean device makers face no legal exposure at all. The Court noted that lawsuits claiming a company failed to follow the FDA's own approved specifications are not blocked, since such claims parallel rather than add to federal requirements. But the Riegels had not properly raised that argument, so their broader safety and design claims were barred.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Patients hurt by an FDA-approved medical device generally cannot sue the manufacturer in state court over the device's design or warnings, closing off a major avenue of compensation for some of the most seriously injured patients. Device makers gain significant protection from lawsuits, while patients are left largely dependent on FDA oversight and any federal compensation programs Congress might later create.
What changes now
This is a final merits ruling, not a remand for further factfinding on the preempted claims. The Second Circuit's judgment affirming dismissal of the Riegels' claims stands. The Court expressly left unresolved whether the lawsuit could proceed on a 'parallel claim' theory — that Medtronic violated the FDA's own requirements — because the Riegels had not raised that argument earlier, and it declined to address defects that surface only after approval.
What this does not decide
The Court did not decide whether lawsuits claiming a company violated the FDA's own requirements (so-called 'parallel claims') survive preemption, since the Riegels raised that theory too late. It also did not address preemption where a device's defect is discovered only after the FDA already approved it.
Concurrences and dissents
Concurrence in part — Justice Stevens
Justice Stevens agreed the MDA's text preempts differing state requirements and joined the judgment and nearly all of the majority opinion, but declined to join the Court's speculation about Congress's underlying policy tradeoffs. He agreed with Justice Ginsburg's account of the law's actual history and purpose, even while concluding the statutory text still compels preemption.
Dissent — Justice Ginsburg
“It is “difficult to believe that Congress would, without comment, remove all means of judicial recourse” for large numbers of consumers injured by defective medical devices.”Ginsburg's central objection that Congress could not have silently eliminated injured patients' ability to sue.
Justice Ginsburg argued Congress never intended the preemption clause to wipe out state tort suits over defectively designed or labeled devices, noting the law's history shows lawmakers wanted to add consumer protections, not remove them. She pointed out that decades of similar FDA drug approval have coexisted with tort suits, and warned the ruling leaves badly injured patients with no remedy at all. She would have reversed and let the suit proceed.
How the Court got there
The legal reasoning, step by step
- The Court first asked whether the federal government had imposed 'requirements' specific to this catheter, since the federal preemption law only blocks state rules that conflict with existing federal requirements. It concluded that the FDA's rigorous premarket-approval process, which reviews a device's exact design, labeling, and manufacturing specifications for safety, counts as such a specific federal requirement.
- The Court distinguished this from an earlier case, Lohr, which involved a device that reached the market through a faster 'substantial equivalence' process that only checks whether a device resembles an older one, not whether it is independently safe — that faster process does not create the kind of specific federal requirement needed for preemption.
- The Court then asked whether New York's common-law duties of care count as 'requirements' that could conflict with the federal ones. It held that jury verdicts in negligence and defect lawsuits do impose legal obligations just as statutes and regulations do, so they qualify as state 'requirements' under the ordinary meaning of that word.
- The Court rejected the argument that only device-specific state rules can be preempted, holding that even general tort duties count as requirements 'with respect to' a device when a lawsuit asks a jury to require something different from what the FDA approved.
- Because the lawsuit's design, labeling, and manufacturing claims would impose safety standards different from the FDA-approved specifications, the Court held those claims were barred, while leaving open claims that a device violated the FDA's own requirements.
Doctrinal impact
Cases affected by this decision
Reaffirms Lohr (518 U. S. 470)
The Court relies on and extends Lohr's framework for deciding when federal device rules preempt state tort claims.